Tennessee Oncology | Association Partnerships

September 06, 2022

Erika P. Hamilton, MD, discusses the background of a phase 1 trial of DS-6000a in patients with advanced renal cell carcinoma and ovarian cancer.

August 24, 2022

In an interview with Targeted Oncology, Erika P. Hamilton, MD, discussed the early clinical activity seen with DS-6000a in patients with advanced ovarian cancer or renal cell carcinoma with disease progression following standard of care treatment.

July 27, 2022

Erika P. Hamilton, MD, discusses the evolution of fam-trastuzumab deruxtecan-nxki through its examination in various trials.

June 22, 2022

Jesus G. Berdeja, MD, director of multiple myeloma research at Sarah Cannon Research Institute and hematology specialist at Tennessee Oncology, discusses the results of the CARTITUDE-1 trial for chimeric antigen receptor T-cell therapy with the newly-approved agent ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.

June 20, 2022

In an interview with Targeted Oncology, Erika Hamilton, MD, discussed the key takeaways of the updated safety analysis of the DESTINY-Breast03 trial.

May 26, 2022

During a Targeted Oncology case-base roundtable event, Jesus G. Berdeja, MD, moderated a discussion around a 55-year-old Black man with late-stage multiple myeloma being treated in a rural community.